Cell Proliferation News and Research

RSS

New lung cancer therapy with vaporized viral vector shows promise

A new lung cancer therapy employing a vaporized viral vector to deliver a cancer-inhibiting molecule directly to lung tissue shows early promise in mouse trials, according to researchers at the Ministry of Education, Science and Technology in Korea.

9 Jun 2009

Cisplatin doubles lung cancer survival time in mice

A lung cancer treatment that inhibits nicotine receptors was shown to double survival time in mice, according to Italian researchers.

9 Jun 2009

Combination of temsirolimus and bryostatin appears safe and active in metastatic kidney cancer

Fox Chase Cancer Center investigators report that a two-drug blockade of mTOR signaling appears safe in metastatic kidney cancer in a phase I trial. Early data suggests that a combination of temsirolimus and bryostatin may be active in patients with rare forms of renal cell cancer, which are less likely to respond to other targeted therapies.

31 May 2009

To spread, skin cancer attacks immune dendritic cells

Dendritic cells are the sentinels of the immune system. When they're alert and on guard, they will marshal the body's immunosoldiers, T cells, to battle at the sight of harmful pathogens. But some diseases, such as cancer, are able to escape their watchful eye. By knocking out or beguiling dendritic cells, they slip the defenses of the immune system and sack the unsuspecting body.

27 May 2009

Discovery of a fundamental mechanism for cell organization

Scientists have discovered that cells use a very simple phase transition -- similar to water vapor condensing into dew -- to assemble and localize subcellular structures that are involved in formation of the embryo.

22 May 2009

Discovery of mutant genes in acute lymphoblastic leukemia

A research team has pinpointed a new class of gene mutations, which identify cases of childhood acute lymphoblastic leukemia (ALL) that have a high risk of relapse and death. The finding suggests specific drugs that could treat this high-risk leukemia subtype in children, particularly because such drugs are already in clinical trials for similar blood diseases in adults.

19 May 2009

New insight into primate eye evolution

Researchers comparing the fetal development of the eye of the owl monkey with that of the capuchin monkey have found that only a minor difference in the timing of cell proliferation can explain the multiple anatomical differences in the two kinds of eyes.

18 May 2009

Determining success or failure in cholesterol-controlling drugs

Researchers at the University of California, San Diego have discovered that a complex network of interactions between drugs and the proteins with which they bind can explain adverse drug effects. Their findings suggest that adverse drug effects might be minimized by using single or multiple drug therapies in order to fine-tune multiple off-target interactions.

15 May 2009

Discovery of genetic cause of luminal-type tumors

The discovery of tumor-suppressor genes has been key to unlocking the molecular and cellular mechanisms leading to uncontrolled cell proliferation - the hallmark of cancer. Often, these genes will work in concert with others in a complex biochemical system that keeps our cells growing and dividing, disease free.

12 May 2009

Discovery of process that controls T cell growth

Identifying one of the processes that plays a role in naïve and memory T-cells' growth and production could one day lead to better vaccines and possibly more effective cancer immunotherapy, said researchers at Baylor College of Medicine and Texas Children's Hospital in a report that appears in the current edition of Nature Immunology.

3 May 2009

Stem cell focus for inflammatory bowel disease wound healing

Scientists at The University of Nottingham are investigating whether stem cell markers could have a role to play in speeding up wound healing in patients suffering from inflammatory bowel disease (IBD).

30 Apr 2009

Peregrine's PS-targeting antibodies highlighted in AACR Annual Meeting studies

Peregrine Pharmaceuticals, Inc. has reported that two preclinical studies presented during the AACR 100th Annual Meeting 2009 provided further confirmation of the immunomodulatory mechanisms contributing to the anti-tumor activity of its phosphatidylserine (PS) targeting antibodies.

22 Apr 2009

How cells control the great divide

A scientist whose work is key to understanding how cancer cells divide and spread in the body is to present advances in his latest research at a public forum to be held at the University of Leicester.

22 Apr 2009

New drug to target tumor cells and blood vessels

Researchers at the University of Southern California have identified a new drug compound that appears to target tumor cells and surrounding blood vessels without the negative side effects typically associated with Cox-2 inhibitors.

21 Apr 2009

New drug to target tumor cells and blood vessels

21 Apr 2009

New information on molecular biology of KRas protein

KRas is one of the usual suspects in cancer. It is a protein that is mutated in 30% of human tumors and has been implicated in the regulation of many cell signalling pathways.

20 Apr 2009

New insights into transcription factors in human cells

Bioinformatics researchers from UC San Diego just moved closer to unlocking the mystery of how human cells switch from "proliferation mode" to "specialization mode."

20 Apr 2009

Addition of dasatinib to standard chemo cocktail may enhance effect in certain ovarian cancers

The addition of a chemotherapeutic drug for leukemia to a standard regimen of two other chemotherapy drugs appears to enhance the response of certain ovarian cancers to treatment, according to a pre-clinical study led by researchers in the Duke Comprehensive Cancer Center.

20 Apr 2009

Do patients at risk for B-cell malignancy need antiviral treatment?

Some studies have shown that a relationship of hepatitis C (HCV) infection with type II mixed cryoglobulinemia exists.

15 Apr 2009

Experimental drug lowers PSA levels

A new multi-center study shows that an experimental drug lowers prostate specific antigen (PSA) levels – a marker for tumor growth – in men with advanced prostate cancer for whom traditional treatment options have failed.

9 Apr 2009